-

$undefined

N/A

(N/A)

Spruce Biosciences OTC Markets OTCPK:SPRB Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company is engaged in the development of TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with MPS IIIB (Sanfilippo Syndrome Type B). It also provides the development stage of Tildacerfont, aimed at treating a highly debilitating mental disorder characterized by depressed mood, cognitive-affective changes, somatic alterations including anhedonia, weight fluctuations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. Spruce Biosciences has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. Furthermore, it has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Location: 611 Gateway Boulevard, South San Francisco, CA, 94080, United States | Website: https://sprucebio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-20.38M

Cash

25.62M

Avg Qtr Burn

-13.43M

Short % of Float

2.05%

Insider Ownership

11.73%

Institutional Own.

41.35%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Details Sanfilippo Syndrome Type B (MPS IIIB)	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tildacerfont Details Major Depressive Disorder (MDD)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tildacerfont Details Polycystic ovary syndrome	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tildacerfont Details Congenital adrenal hyperplasia, Primary biliary cholangitis, Liver disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tildacerfont Details Congenital adrenal hyperplasia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.